CCR2 Inhibitor

DOTA-ECL1i is a conjugate of the CCR2 inhibitor ECL1i (HY-P11553) and DOTA. When radiolabeled with ⁶⁸Ga, DOTA-ECL1i serves as a PET tracer that targets CCR2 expression. DOTA-ECL1i can be used in research related to pulmonary fibrosis, cardiac injury, abdominal aortic aneurysm inflammation, atherosclerosis, head and neck cancer, and pancreatic cancer.

Viscumneoside V is a plant-derived anti-inflammatory agent present in Viscum album var. coloratum. Viscumneoside V inhibits the expression of MCP-1 and promotes the production of RANTES in LPS-stimulated immune cells. Viscumneoside V can be used for research related to skin rashes.

Plozalizumab (MLN-1202) is a humanized anti-CCR2 IgG1 monoclonal antibody. Plozalizumab blocks the recruitment of myeloid cells to the tumor microenvironment by inhibiting the CCL2/CCR2 axis. In addition, Plozalizumab also ameliorates synovial inflammation in rheumatoid arthritis. Plozalizumab can be used in the research of malignant melanoma and bone metastasis-related cancers. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).

CCX140 (CCX140-B) is a potent CCR2 antagonist.

CCR2-IN-1 (Compound HO11553-TM) is a G protein-coupled receptor CCR2 inhibitor. CCR2-IN-1 slows the progression of idiopathic pulmonary fibrosis. CCR2-IN-1 can be used for the research of idiopathic pulmonary fibrosis.

JNJ-41443532 (CCR2 antagonist 5) is a selective, orally active hCCR2 inhibitor with good binding affinity (IC₅₀=37 nM) and potent functional antagonism (chemotaxis IC₅₀=30 nM). JNJ-41443532 displays a K_i of 9.6 µM for mCCR2 binding. JNJ-41443532 can be used in the research of inflammatory disease.

ECL1i is an allosteric, selective CCR2 inhibitor. ECL1i specifically inhibits CCL2-/CCR2-mediated chemotaxis. ECL1i interferes with CCR2-positive cell recruitment and attenuates disease progression in experimental autoimmune encephalomyelitis.

Emapticap pegol scramble negative control, an oligonucleotide aptamer, is the negative control of Emapticap pegol (HY-148100).

Anti-Mouse CCR2 Antibody (C2Mab-6) is a monoclonal antibody targeting mouse CC chemokine receptor type 2 (mCCR2), with a K_D value of 0.18-1.6 nM. Anti-Mouse CCR2 Antibody (C2Mab-6) exhibits high binding affinity to cells expressing mCCR2 and shows no reactivity to parental CHO-K1 cells. Anti-Mouse CCR2 Antibody (C2Mab-6) recognizes the amino acid region spanning positions 1-19 of mCCR2, and its key binding epitope includes Asp3, Asn4, Met6, Pro8, Gln9 and Phe10. Anti-Mouse CCR2 Antibody (C2Mab-6) can be used in leukemia-related research.